NIR Prediction of Solid Dosage Form Dissolution Profiles - Foss Whitepaper

mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

The new facility offers cleanroom packaging and high-sensitivity analytical testing.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

The agreement has been designed to offer a turnkey service to companies seeking faster time to market.

Most of the company’s new additions, if not already online, will be scheduled for commissioning, validation, or qualification before the fourth quarter of 2025.